

**BME - GROWTH**

Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, 24<sup>th</sup> January 2024

**COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.**

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17<sup>th</sup> March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “FacePhi” or “the Company”, interchangeably).

The Company published, in 21<sup>st</sup> July of 2023, the resolutions adopted by the Extraordinary General Shareholders’ Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue notes convertible into shares of the Company in favour of Nice & Green, S.A. (“Nice & Green”), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said notes.

Last 22<sup>nd</sup> of January, the Board of Directors adopted a resolution, under the aforementioned delegation of powers, to issue a third issuance of 60 convertible bonds for a total nominal amount of 600,000 euros (“Convertible Bonds 1<sup>st</sup> Tranche 24”), and Nice & Green is the sole beneficiary of this issuance.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

---

Javier Mira Miró

**Chairman of the Board of Directors**